SCHEMBL4912447

SCHEMBL4912447

CC(C)c1ccc(NC(=O)Nc2nccs2)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.72
MEN1 O00255 4/20 0.72
KMT2A Q03164 4/20 0.72
SMN1; SMN2 Q16637 3/20 0.72
CYP1A2 P05177 1/20 0.72
CYP2D6 P10635 1/20 0.72
CYP2C9 P11712 1/20 0.72
CYP2C19 P33261 1/20 0.72
CASP3 P42574 1/20 0.72
HTT P42858 1/20 0.72
SENP8 Q96LD8 1/20 0.72
SENP7 Q9BQF6 1/20 0.72
SENP6 Q9GZR1 1/20 0.72
LMNA P02545 4/20 0.67
TP53 P04637 2/20 0.67
TSHR P16473 2/20 0.67
AURKA O14965 1/20 0.67
PIM1 P11309 1/20 0.67
CDK2 P24941 1/20 0.67
GSK3B P49841 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4915214 0.84 SMN1; SMN2 (0.73) MAPTMEN1KMT2ASMN1; SMN2CYP1A2
SCHEMBL27861124 0.84 SMN1; SMN2 (0.73) MAPTMEN1KMT2ASMN1; SMN2CYP1A2
SCHEMBL7261477 0.81 SMN1; SMN2 (0.73) MAPTMEN1KMT2ASMN1; SMN2CYP1A2
SCHEMBL4600722 0.80 AURKA (1.00) MAPTMEN1KMT2ASMN1; SMN2CYP1A2
SCHEMBL19707622 0.79 RAB9A (0.76) MAPTMEN1KMT2ASMN1; SMN2TP53
Isobutyraldehyde SCHEMBL27611952 0.77 SMN1; SMN2 (0.56) MAPTMEN1KMT2ASMN1; SMN2CYP1A2
SCHEMBL1340309 0.77 LMNA (0.50) MAPTMEN1KMT2ASMN1; SMN2CYP1A2
SCHEMBL7690800 0.77 MAPT (0.78) MAPTMEN1KMT2ASMN1; SMN2CYP1A2
SCHEMBL28010665 0.76 MAPT (0.69) MAPTMEN1KMT2ASMN1; SMN2CYP1A2
SCHEMBL6284915 0.76 CDK2 (0.78) MAPTMEN1KMT2ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US claimed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US claimed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R MAPT 4151/4885MEN1 4843/4885KMT2A 1905/4885
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R MAPT 4151/4885MEN1 4843/4885KMT2A 1905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.